433 related articles for article (PubMed ID: 30730278)
1. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
[TBL] [Abstract][Full Text] [Related]
2. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
3. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita S; Ogasawara S; Nakagawa M; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kogure T; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Kato J; Kato N
BMC Gastroenterol; 2023 Mar; 23(1):101. PubMed ID: 37003980
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
[TBL] [Abstract][Full Text] [Related]
6. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
7. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
8. [Advances in Hyperprogressive Disease in Patients
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
Yao S; Shi K; Zhang Y
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
[TBL] [Abstract][Full Text] [Related]
9. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.
Petrioli R; Mazzei MA; Giorgi S; Cesqui E; Gentili F; Francini G; Volterrani L; Francini E
Anticancer Drugs; 2020 Feb; 31(2):190-195. PubMed ID: 31850916
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
Shen P; Han L; Ba X; Qin K; Tu S
Front Pharmacol; 2021; 12():678409. PubMed ID: 34290608
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.
Liu X; Qiao L
Front Nutr; 2022; 9():810472. PubMed ID: 35399666
[TBL] [Abstract][Full Text] [Related]
14. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
[TBL] [Abstract][Full Text] [Related]
19. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
20. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
